Latest news with #Kenvue
Yahoo
6 days ago
- Business
- Yahoo
S&P 500 Gains & Losses Today: Dollar General Stock Soars as Discount Retailer Posts Solid Results
The S&P 500 advanced 0.6% on Tuesday, June 3, 2025, as a report showing a surprise increase in job openings last month signaled labor-market resilience. Dollar General shares skyrocketed after the discount retailer beat quarterly estimates, raised its outlook, and expressed confidence in its capacity to mitigate tariff impacts. Shares of Kenvue lost ground as the consumer health supplier's CEO discussed softness in seasonal U.S. equities indexes finished higher after data from the Bureau of Labor Statistics showed an unexpected uptick in job openings in April, although several economists cautioned that tariffs could weigh on jobs growth as the year advances. The S&P 500 ended Tuesday's session 0.6% higher. The Dow added 0.5%. Strength among semiconductor firms and the rest of the tech sector helped lift the Nasdaq 0.8%. Read Investopedia's full daily markets roundup here. Dollar General (DG) shares surged 16%, chalking up the S&P 500's top daily performance after the discount retailer topped quarterly sales and profit estimates and boosted its full-year outlook. The company anticipated that it should be able to mitigate most tariff-related cost pressure but expressed uncertainty around the possible impact on consumer spending trends. Analysts have said that dollar stores could be poised to benefit as consumers trade down in the current environment. Shares of Dollar Tree (DLTR), set to report its own results Wednesday morning, were up 6%. Shares of ON Semiconductor (ON) jumped 11% after the company's top executive discussed expectations for a recovery in demand. In a presentation at the Bank of America Technology Conference, Onsemi CEO Hassane El-Khoury pointed to signs of recovery in the company's industrials market, its second largest, as well as indications that the automotive market could see a bottom in the second quarter. First Solar (FSLR) stock bounced 6.5% higher on Tuesday, reversing losses posted in the prior session. Shares of companies in the renewable energy space have come under pressure since the House passed a reconciliation bill that calls for the elimination of numerous clean energy initiatives and the Department of Energy cancelled an array of related grants. Mizuho analysts boosted their price target on the stock. Crude oil futures prices extended their recent string of gains, bolstered by increasing geopolitical tensions, including an escalation of the war in Ukraine and an uncertain outlook for a U.S.-Iran nuclear deal. The price uptick helped lift oil and gas stocks, with shares of exploration and production firm APA Corp. (APA) gaining 5.4%. Shares of Kenvue (KVUE), the consumer health company that spun off from Johnson & Johnson (JNJ) in 2023, dropped 6.2%, the furthest of any S&P 500 stock. Kenvue CEO Thibaut Mongon suggested that a lagging transition from spring into winter had contributed to soft seasonal demand for allergy and sun protection products. FactSet Research Systems (FDS) shares sank 4.8% after the financial data and software provider announced that Sanoke Viswanathan, formerly an executive at JPMorgan Chase (JPM), would take the reins as CEO starting in September. Current CEO Phil Snow is set to retire and exit his position on FactSet's board of directors at that time. Read the original article on Investopedia Sign in to access your portfolio
Yahoo
6 days ago
- Business
- Yahoo
Kenvue Leads S&P 500 Decliners as CEO Points to Seasonal Demand Challenges
Shares of Kenvue (KVUE) led S&P 500 decliners Tuesday after the consumer health giant's chief executive indicated the firm faces seasonal demand challenges. Speaking at Deutsche Bank's dbAccess Global Consumer Conference, Kenvue CEO Thibaut Mongon highlighted the importance of seasonality for its allergy products, like Benadryl and Zyrtec. "We saw a longer winter, so winter pushed spring into later in Q2," Mongon said, according to a transcript provided by AlphaSense. "So we see that on allergy where we saw a later start to the season, and so far, it's below last year." Mongon also noted similar seasonal troubles for its sun protection brands, like Neutrogena and Aveeno. "In sun, we see more or less the same. Late start to the season year-to-date behind last year, but the season has not really started for recreational sun, and Memorial Day weekend was just a few days ago," Mongon said. "It was not great, as you and I could see. But, again, we are just at the beginning of the season. So it's too early to read the season. It will certainly impact Q2." Kenvue shares were down more than 7% in recent trading. With today's sharp declines, the stock's year-to-date gains stand at less than 3%. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-06-2025
- Business
- Yahoo
Tylenol Has Launched Its First Supplement to Support Muscle and Joint Health
Tylenol is betting big on the supplement market. The company best known for its pain relief medications featuring acetaminophen on Monday is entering the supplement category with its base product Proactive Support From the Makers of Tylenol, $20, a muscle and joint support supplement and an additional product with added stress support for $24, both available at all retailers where Tylenol is sold. This marks the company's first foray into drug-free pain solutions. Both products come with a month's worth supply of a single daily capsule. More from WWD Dianna Singh Is Taking Beauty Cues for Her Fashion Brand EXCLUSIVE: Fifteen Years After Hitting the Market With Its Signature Greens, AG1 Is Launching a Sleep Supplement Can Beauty Dupes Coexist With - or Even Benefit - the Products That Inspire Them? According to the Tylenol team, the move into supplements was strategic in order to be able to offer consumers both reactive support with medication and proactive support with this new product. 'I constantly heard from consumers and pain sufferers that they want a full, robust toolkit to manage their pain,' said Jennifer Gow, head of U.S. pain at Kenvue, who has worked at Johnson & Johnson and now Kenvue for the past 17 years. 'Being the leader of the category and being Tylenol, it made sense for us to provide both drug and non-drug solutions… We hear from consumers that they want to be more proactive about managing [and] preventing pain.' According to Gow, the team had always been exploring the opportunity to enter this category, and given the increased consumer demand and discovery of a differentiated formula, now was the right time. The product specifically uses a proprietary blend of turmeric and tamarind called TamaFlex, as well as cucumber extract, which are clinically studied ingredients that show joint and flexibility supporting properties. According to the company, the product should start working within five days compared to a leading competitor at seven days. The version with added stress-relief benefits is also formulated with sceletium extract for its calming effects. 'We talked to health care professionals, and 84 percent of them said they would consider providing this specific formula,' Gow said. While Tylenol is targeting a variety of consumers who may experience pain with this launch, Gow identified a few specific ones, particularly those 40-plus. 'Recently, we have been reaching out to our transitional consumer… or that type of consumer who is going from acute, occasional pain to more regular, but it isn't always on a daily basis. Those transitional consumers are the people who can start being more proactive about their health,' she said. In addition, Gow pointed to perhaps a more niche consumer but a still important market, such as the person in their 20s experiencing joint pain from marathon training. It's also an ideal support product for someone experiencing chronic pain to help manage symptoms. 'You don't age out of this product, but the earlier you can start, as you're starting to feel that joint discomfort, that's the best time to be more proactive about this,' said Gow. As these products launch, they will be strategically placed directly next to Tylenol on the pain aisle rather than merchandised with other supplements. According to Gow, the company surveyed consumers and an overwhelming amount said they would want to see it in retail this way. To introduce the product, the company is employing traditional national media as well as tapping comedian and actress Molly Shannon for content that will be used primarily on social media. 'She's going to be talking a lot about this launch, and how she had a very active comedic career, and to stay active now, she partners with us and takes Tylenol Proactive Support, as well as all of the other things that she needs to do to stay active,' said Gow. In addition, the company will partner with other creators and experts to discuss their pain prevention routines, including this new product, sleep, exercise and more. As far as expanding in the supplement category, there could be more to come. 'I see big opportunities for us in the future. We're partnering with our research and development team to see what's next,' Gow said.
Yahoo
02-06-2025
- Business
- Yahoo
Kenvue Debuts on Fortune 500 List
SUMMIT, N.J., June 02, 2025--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. "Being named to the Fortune 500 list marks a significant milestone for Kenvue," said Thibaut Mongon, Chief Executive Officer. "Recognitions like this validate the hard work and dedication of our Kenvuers, while also further propelling our desire to become the undisputed global leader in consumer health. We are honored to join this elite group of companies and look forward to continuing our journey of growth and impact." Operating in over 165 countries worldwide, Kenvue is comprised of a curated portfolio of Essential Health, Self Care, and Skin Health & Beauty brands reaching approximately 1.2 billion people daily. Its global workforce of more than 20,000 purpose-led, values-based Kenvuers are driven to make a meaningful impact on the health of people and the planet. By combining the power of science with deep human insights and cutting-edge technology, Kenvue is poised to use its size and scale as a Fortune 500 company to take a leadership role in the wellness revolution - placing its products and solutions at the center of everyday care rituals, today and into the future. Now in its 71st year, the Fortune 500 is Fortune magazine's annual list of the 500 largest U.S. companies ranked by total revenues for their respective fiscal years. The list is compiled using the most recent revenue figures and includes both public and private companies. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers' hands and earn a place in their hearts and homes. Learn more at View source version on Contacts Investor Relations: Sofya TsinisKenvue_IR@ Media Relations: Melissa WittMedia@ Sign in to access your portfolio
Yahoo
02-06-2025
- Business
- Yahoo
Kenvue Debuts on Fortune 500 List
SUMMIT, N.J., June 02, 2025--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. "Being named to the Fortune 500 list marks a significant milestone for Kenvue," said Thibaut Mongon, Chief Executive Officer. "Recognitions like this validate the hard work and dedication of our Kenvuers, while also further propelling our desire to become the undisputed global leader in consumer health. We are honored to join this elite group of companies and look forward to continuing our journey of growth and impact." Operating in over 165 countries worldwide, Kenvue is comprised of a curated portfolio of Essential Health, Self Care, and Skin Health & Beauty brands reaching approximately 1.2 billion people daily. Its global workforce of more than 20,000 purpose-led, values-based Kenvuers are driven to make a meaningful impact on the health of people and the planet. By combining the power of science with deep human insights and cutting-edge technology, Kenvue is poised to use its size and scale as a Fortune 500 company to take a leadership role in the wellness revolution - placing its products and solutions at the center of everyday care rituals, today and into the future. Now in its 71st year, the Fortune 500 is Fortune magazine's annual list of the 500 largest U.S. companies ranked by total revenues for their respective fiscal years. The list is compiled using the most recent revenue figures and includes both public and private companies. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers' hands and earn a place in their hearts and homes. Learn more at View source version on Contacts Investor Relations: Sofya TsinisKenvue_IR@ Media Relations: Melissa WittMedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
